Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Articles

Superoxide Modulates Myogenic Contractions of Mouse Afferent Arterioles

En Yin Lai, Anton Wellstein, William J. Welch, Christopher S. Wilcox
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.111.170472
Hypertension. 2011;58:650-656
Originally published September 14, 2011
En Yin Lai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anton Wellstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Welch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher S. Wilcox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods and Protocols
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Reactive oxygen species enhance or impair autoregulation. Because superoxide is a vasoconstrictor, we tested the hypothesis that stretch generates superoxide that mediates myogenic responses. Increasing perfusion pressure of mouse isolated perfused renal afferent arterioles from 40 to 80 mm Hg reduced their diameter by 13.3±1.8% (P<0.001) and increased reactive oxygen species (ethidium: dihydroethidium fluorescence) by 9.8±2.3% (P<0.05). Stretch-induced fluorescence was reduced significantly (P<0.05) by incubation with Tempol (3.7±0.8%), pegylated superoxide dismutase (3.2±1.0%), or apocynin (3.5±0.9%) but not by pegylated catalase, l-nitroarginine methylester, or Ca2+-free medium, relating it to Ca2+-independent vascular superoxide. Compared with vehicle, basal tone and myogenic contractions were reduced significantly (P<0.05) by pegylated superoxide dismutase (5.4±0.8), Tempol (4.1±1.0%), apocynin (1.0±1.3%), and diphenyleneiodinium (3.9±0.9%) but not by pegylated catalase (10.1±1.6%). l-Nitroarginine methylester enhanced basal tone, but neither it (15.8±3.3%) nor endothelial NO synthase knockout (10.2±1.8%) significantly changed myogenic contractions. Tempol had no further effect after superoxide dismutase but remained effective after catalase. H2O2 >50 μmol/L caused contractions but at 25 μmol/L inhibited myogenic responses (7.4±0.8%; P<0.01). In conclusion, increasing the pressure within afferent arterioles led to Ca2+-independent increased vascular superoxide production from nicotinamide adenine dinucleotide phosphate oxidase, which enhanced myogenic contractions largely independent of NO, whereas H2O2 impaired pressure-induced contractions but was not implicated in the normal myogenic response.

  • oxidative stress
  • reactive oxygen species
  • hydrogen peroxide
  • renal autoregulation
  • hypertension

Introduction

Autoregulation maintains renal blood flow, glomerular filtration rate, and tubular fluid delivery during changes in perfusion pressure (PP).1 Defects in the buffering of arterial pressure by renal autoregulation have been implicated in renal barotrauma.2 Renal autoregulation depends primarily on a rapid myogenic contraction of the afferent arteriole3 followed by a tubuloglomerular feedback response.1,3

Myogenic mechanisms in the afferent arteriole are incompletely understood.1 Reactive oxygen species (ROS) have been implicated in the increased vascular reactivity of the renal afferent arterioles to angiotensin II in states of oxidative stress.4–6 An increase in pressure in a large conduit artery increased vascular ROS generation by NADPH oxidase, but conduit arteries have little myogenic reactivity.7 Recently, ROS have been implicated in the enhanced myogenic contractions of renal afferent arterioles from spontaneously hypertensive rats (SHRs),8 although the more modest myogenic contractions of normotensive rats were independent of ROS.8 On the other hand, ROS may impair autoregulation. Thus, rat kidneys with oxidative stress caused by transforming growth factor-β9 or by a high salt intake and angiotensin II infusion10 had impaired myogenic responses that were preserved by the redox-cycling nitroxide Tempol,11 whereas exposure of cerebral arterioles to ROS abolished autoregulation.12 Therefore, it is presently unclear whether ROS contribute positively or negatively to myogenic responses.13 This could indicate different effects of superoxide (O2 · −), which was a potent stimulator of vascular reactivity,4,5 and hydrogen peroxide (H2O2), which had variable effects.14,15

The mouse isolated perfused renal afferent arteriole displayed a linear increase in active wall tension above a PP of ≈40 mm Hg, which defined the myogenic response.16 We used this preparation to test the hypothesis that stretch increased ROS and that O2 · − and/or H2O2 were required for the myogenic contraction. We loaded vessels with dihydroethidium, which is a ROS-sensitive fluorophore, to determine release of ROS by increased PP. Tempol was added to the bath to metabolize ROS. Because Tempol can metabolize both O2 · − and H2O2, the ROS responsible was assessed from the effects of bath addition of pegylated superoxide dismutase (PEG-SOD) or pegylated catalase (PEG-CAT), which are taken up into cells and metabolized O2 · − or H2O2, respectively.17 Although we found no effects of PEG-CAT on myogenic contractions in afferent arterioles from normal mice, we investigated the effects of bath addition of H2O2 on basal contractility and myogenic responses to determine its potential role in states of vascular oxidative stress. The source of ROS was assessed from the effects of bath addition of apocynin, diphenyleneidinium, or l-nitroarginine methyl ester (l-NAME). Apocynin inhibited NADPH oxidase in renal afferent arterioles,8 and l-NAME blocked ROS derived from uncoupled endothelial NO synthase (eNOS).18 ROS have direct effects on vascular smooth muscle cell contractility11 or indirect effects via bioinactivation of NO by O2 · −.19 NO blunted myogenic contractions in vivo in rat kidneys, but this was ascribed to an indirect effect via tubuloglomerular feedback20 and blunted contractions in rabbit afferent arterioles but only when NO generation was stimulated by vascular flow.21 Therefore, we assessed the effects of NO on myogenic responses by blockade of NO synthase with l-NAME and in mice with a knockout of eNOS (eNOS−/−). Ca2+ is essential for myogenic responses, but its relationship to vascular smooth muscle cell ROS is not established.22 Therefore, we assessed myogenic responses and PP-induced ROS in Ca2+-free medium.

Methods and Protocols

Male C57BL/6 mice, aged 3 to 5 months and weighing 25 to 28 g (Jackson Laboratory, Bar Harbor, ME), were fed a 0.4% NaCl (normal) control test diet (Harlan Teklad) and allowed free access to tap water. Additional studies were undertaken in eNOS knockout mice from Jackson Laboratories. All of the procedures conformed to the Guide for Care and Use of Laboratory Animals prepared by the Institute for Laboratory Animal Research. Studies were approved by the Georgetown University Animal Care and Use Committee. Details of methods appear in the online Data Supplement (please see http://hyper.ahajournals.org).

Animal Preparation, Dissection, and Mounting of Afferent Arterioles and Surgery

Mice were anesthetized with 2% isoflurane and oxygen, the kidneys were removed, and a single renal afferent arteriole was prepared as described in detail16 and in the online Data Supplement.

Measurements of ROS and Myogenic Responses in Afferent Arterioles

These were as described previously16,22–24 and detailed further in the online Data Supplement.

Pharmacological Agents

The drugs used were as follows: 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy (Tempol), superoxide dismutase-polyethylene glycol, catalase-polyethylene glycol, apocynin, diphenyleneiodinium (DPI), l-NAME, and H2O2 from Sigma-Aldrich. Drugs were added to the bath 30 minutes before testing in the concentrations shown to be effective.

Statistics

Data were expressed as mean±SEM. An ANOVA compared the effects of vehicle and drugs added to the bath. When appropriate, these calculations were followed by Bonferroni post hoc Student t tests. Changes were analyzed using nonparametric statistics (GraphPad Prism, GraphPad Software). P<0.05 was considered statistically significant.

Results

Data in arterioles from normal mice are shown in Figure S1 in the online Data Supplement (please see http://hyper.ahajournals.org). Increasing renal PP from 40 to 80 mm Hg increased the fluorescent signal for ROS, detected as the ratio of ethidium:dihydroethidium by 9.8±2.3% (Figure 1). The ROS signal was significantly (P<0.01) reduced by incubating with PEG-SOD (3.2±1.0%), Tempol (3.7±0.8%), or apocynin (3.5±0.9%), but it was not affected by PEG-CAT (10.2±1.9%) or l-NAME (11.8±2.8%) or removal of external Ca2+ with Ca-free bath and EGTA (11.7±3.2%).16 The increase in vascular ROS with increased PP detected with ethidium:dihydroethidium was similar to that detected by tempo-9AC (n=4), which was increased by 10.4±1.6%.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Mean±SEM values (n=5 to 6) for change in ethidium to dihydroethidium fluorescence of afferent arterioles after increasing perfusion pressure from 40 to 80 mm Hg with 30-minute incubation in vehicle, 1000 μ t· tmL−1 pegylated catalase, 200 μ t· tmL−1 pegylated superoxide dismutase, 10−4 m Tempol, 10−5 m apocynin, 10−4 m l-nitroarginine methyl ester (l-NAME), or in a calcium-free medium with EGTA. Compared with vehicle: **P<0.01.

The effects of addition of Tempol to the bath on the diameter of isolated renal afferent arterioles perfused at 60 mm Hg are shown in Figure 2. Tempol caused graded increases in vascular diameter that were maximal at ≈10−4 m (14.4±2.2%; Figure 2A). The relaxation occurred over the first 6 minutes and was stable by ≈15 minutes (Figure 2B). Therefore, a dose of 10−4 m Tempol and an incubation time of 30 minutes were selected for these studies. The basal diameter was also increased by incubation of arterioles with 200 u · mL−1 PEG-SOD (12.4±0.6%; P<0.001), apocynin (15.4±3.1%; P<0.05), or DPI (8.9±2.5%; P<0.05). After incubation with 200 u · mL−1 of PEG-SOD, the addition of 10−4 m Tempol for 15 minutes did not further increase the basal diameter (3.0±1.5%; P value not significant). The basal diameter was not affected by incubation with 1000 u · mL−1 of PEG-CAT (0.1±0.1%; P value not significant) but was reduced by l-NAME (−9.9±2.7%; P<0.01). After incubation with 1000 μ · mL−1 of PEG-CAT, the addition of 10−4 m Tempol for 15 minutes increased the diameter by 12.2±2.2% (P<0.05), which was similar to Tempol alone.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Mean±SEM values (n=4 to 8) comparing afferent arterioles perfused at 60 mm Hg and incubated with vehicle (solid triangles and continuous lines) or with graded concentrations of Tempol (open triangles and interrupted lines) for change in diameter (A) or for time after addition of vehicle, 10−4 m Tempol, 200 μ t· tmL−1 PEG-SOD (solid squares and continuous lines), 1000 μ t· tmL−1 PEG-CAT (open squares and interrupted lines), 10−5 m apocynin (open circles and interrupted lines), 10−5 m diphenyleneiodinium (DPI; solid circles and continuous lines), or 10−4 m l-nitroarginine methyl ester (l-NAME; crosses and continuous lines; B), or for the effects of incubation with 10−4 m Tempol for the times shown after preincubation for 30 minutes with PEG-SOD (solid triangles and continuous lines) or pegylated catalase (PEG-CAT; open triangles and interrupted lines; C). Comparing differences: *P<0.05; **P<0.01; ***P<0.005.

There were no significant differences in the basal luminal diameter measured at 40 mm Hg between the groups (Table). Compared with vehicle, incubation of the vessels with 10−4 m Tempol, 200 u · mL−1 of PEG-SOD, 10−5 m apocynin, or 10−5 m DPI all attenuated the pressure-induced reduction in diameter (Table and Figure 3A and 3B) without affecting the passive wall tension (Figure 3C), resulting in significant reductions in active wall tension (Figure 3D; myogenic response, Table). Compared with vehicle, the myogenic response was reduced by 71% by Tempol, by 58% by PEG-SOD, by 58% by apocynin, and by 65% by DPI (Table). After preincubation with PEG-SOD, the addition of Tempol had no significant further effect.

View this table:
  • View inline
  • View popup
Table.

Basal Luminal Diameter of Afferent Arterioles and Characteristics of Myogenic Responses During Increases in Perfusion Pressure From 40 to 135 mm Hg After Bath Addition of Vehicle or Drugs

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Mean±SEM values (n=5 to 8) for vessels incubated with a vehicle (solid triangles and continuous lines), 10−4 m Tempol (open triangles and interrupted lines), 200 μ · mL−1 PEG-SOD (solid squares and continuous lines), 10−5 m apocynin (open circles and interrupted lines), 10−5 m diphenyleneiodinium (DPI; solid circles and continuous lines), or PEG-SOD followed by Tempol (open squares and broken lines). Data are shown for diameter (A), change in diameter (B), passive wall tension (C), and active wall tension (D). Comparing groups: **P<0.01; ***P<0.005.

Incubation of vessels with 1000 u · mL−1 of PEG-CAT had no significant effects on the reductions in vessel diameter with increasing PP (Figure 4A and 4B) or the passive or active wall tensions (Figure 4C and 4D) and did not modify the response to 10−4 m Tempol (Table).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Mean±SEM values (n=6 to 8) for vessels incubated with a vehicle (solid triangle and continuous lines), 10−4 m Tempol (open triangle and broken lines), 1000 μ · mL−1 PEG-catalase (solid square and continuous lines) and Tempol after PEG-catalase (open square and broken lines). Comparing groups: *P<0.05; ***P<0.005.

Afferent arterioles were perfused at 60 mm Hg to provide some basal tone and incubated with graded concentration of H2O2 for 15 minutes. H2O2 significantly reduced the diameter at concentrations >50 μmol/L (Figure 5A). A subthreshold concentration of H2O2 of 25 μmol/L blunted the reduction in luminal diameter with PP (Figure 5B) and the myogenic response (Table). Bath addition of l-NAME or use of eNOS−/− mice had no significant effects on changes in vessel diameter with increasing PP (Figure 6A and 6B), passive or active wall tension (Figure 6C and 6D), or myogenic responses (Table).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Mean±SEM values (n=10) in A for vessels perfused at 60 mm Hg and incubated by 30 minutes with graded concentrations of hydrogen peroxide (open triangles and broken lines). In B, vessels were incubated for 30 minutes with vehicle (solid triangles and continuous lines) or 25 μmol · L−1 H2O2 (open triangles and broken line) and perfused at graded pressures. Comparing groups: *P<0.05; **P<0.01; ***P<0.005.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Mean±SEM values (n=6) for vessels incubated with a vehicle (solid triangle and continuous lines) or 10−4 m l-nitroarginine methyl ester (l-NAME; crosses and continuous lines), or vessels from endothelial NO synthase (eNOS−/−) mice (crosses and broken lines). Comparing groups: *P<0.05; **P<0.01; ***P<0.005.

Discussion

The main new findings from this study of afferent arterioles from normal C57BL/6 mice were that increasing the PP from 40 to 80 mm Hg caused a myogenic contraction accompanied by an increase in ROS signal whether detected by dihydroethidium or tempo-9AC. The fluorescent ROS signal was predominately O2 · −, because it was reduced by incubation with PEG-SOD or Tempol but not with PEG-CAT and was upstream from Ca2+ because it persisted in Ca2+-free medium. Incubation of vessels with Tempol, PEG-SOD, apocynin, or DPI reduced basal and myogenic tone, whereas PEG-CAT was not effective, indicating that the responses were enhanced by O2 · − generated from NADPH oxidase. The moderation of myogenic contractions by Tempol was prevented by preincubation with PEG-SOD but was preserved by preincubation with PEG-CAT. H2O2 caused contractions at concentrations >50 μmol/L but inhibited myogenic responses at 25 μmol/L. l- NAME increased basal tone but did not affect pressure-induced ROS generation. Neither l-NAME nor eNOS knockout affected myogenic contractions.

Tempol added to the bath prevented the enhanced angiotensin II contractions of perfused renal afferent arterioles of superoxide dismutase 1−/− mice,6 moderated U-46 619-induced vasoconstriction25 and prevented the endothelium-dependent contractions in rabbits with oxidative stress.5 Tempol is a superoxide dismutase mimetic and reduced tissue O2 · −,11 but it might thereby increase tissue H2O2.11,26–28 However, the increase in H2O2 in blood vessels was modest and lasted <2 minutes.29 Moreover, Tempol is a redox cycling nitroxide11 with catalase-like actions in tissues that prevented H2O2 accumulation.30,31 We found that the pressure-induced increase in fluorescence signal from the oxidation of dihydroethidium was reduced by Tempol, similar to PEG-SOD, but was not reduced by PEG-CAT. This indicated that the ROS generated by vascular stretch was superoxide and that this was inhibited by Tempol. Moreover, Tempol had no further effect on the myogenic response in vessels preincubated with PEG-SOD but retained its full efficacy after PEG-CAT. This related the inhibitory effects of Tempol on the myogenic response to metabolism of O2 · − rather than to increased H2O2. Indeed, myogenic responses were blunted by PEG-SOD but not by PEG-CAT, indicating that the normal myogenic response was enhanced by O2 · − rather than by H2O2. However, although H2O2 was not implicated in normal myogenic responses, it may contribute if it accumulated sufficiently in the vessels, because 25 μmol/L of H2O2 inhibited myogenic contractions. H2O2 also inhibited angiotensin-induced contractions and intracellular calcium in rat afferent arterioles.22 Therefore, the catalase-like activity of Tempol might explain its improvement in myogenic responses in models of severe or prolonged oxidative stress if H2O2 accumulated sufficiently to blunt myogenic contractions in these circumstances.

Apocynin inhibited the enhanced myogenic responses of afferent arterioles from SHRs. Apocynin is not a specific inhibitor of NADPH oxidase.32 However, similar results were obtained by inhibition of NADPH oxidase with gp9lds-tat.8 The finding that apocynin and another NADPH oxidase inhibitor, DPI, had similar effects as Tempol or PEG-SOD in reducing basal and myogenic tone in mouse afferent arterioles in this study confirmed that the source of O2 · − was predominantly NADPH oxidase.7 Because the perfusion pressure–induced increase in contraction was abolished in Ca2+-free medium, yet the increase in ROS was unaffected, we concluded that the myogenic response was entirely dependent on Ca2+ and that changes in Ca2+ concentration or sensitivity were downstream from increased O2 · −.

We found comparable effects of the drugs that blocked O2 · − to reduce basal and active myogenic tone. This suggests that both depended on the generation of O2 · −, consistent with effects of NADPH oxidase to increase basal tone in SHR aortas.33 Blockade of NOS by l-NAME increased the basal tone of the perfused afferent arteriole but did not change perfusion pressure–induced ROS or contractions. Thus, eNOS uncoupling did not contribute to O2 · − generation, and NO did not modulate the myogenic response. Moreover, prolonged deletion of the eNOS gene also did not affect myogenic responses (Figure 6 and Table). This is consistent with the conclusions of Juncos et al21 that the stretch-induced contraction of rabbit isolated afferent arterioles was not dependent on NO, although flow-induced NO release affected basal tone.

The present conclusions differ from previous studies in normal rats where O2 · − contributed to the enhanced myogenic response of SHR afferent arterioles but had little influence under normal conditions.8 Sharma et al9 reported that transforming growth factor-β blocked autoregulatory responses of the rat juxtamedullary nephron preparation by stimulating ROS. Saeed et al10 reported a reduced myogenic response in intact kidney of rats given a high-salt intake and infused with angiotensin II for 14 days that was preserved by Tempol. Clearly, ROS may have opposite modulating effects on myogenic responses that may relate to experimental conditions (isolated arterioles versus intact kidneys), species (rat versus mouse), or ROS ( ·O2 · − versus H2O2). The present study is the first to implicate O2 · − in myogenic responses of afferent arterioles from normal mice.

Perspectives

Glomerular filtration requires a uniquely high capillary pressure that renders the glomerular capillaries susceptible to barotrauma if there is a breakdown of renal myogenic responses and a rise in blood pressure, as in some models of chronic kidney disease.34 Thus, if afferent arteriolar ROS enhance myogenic responses, they might have a renal protective effect. However, the effects of metabolism of ROS by Tempol vary widely from inhibitory effects on acute myogenic responses seen in mice arterioles in this study and in SHRs8 to restorative effects in some others.9,10 Further study will be needed to determine whether these variable effects of Tempol on myogenic responses could underlie some discordant reports of its effects on the kidneys in models of chronic kidney disease that range from renal protection in the reduced renal mass model in rats35 or mice36 to no effect in models of diabetes mellitus28 or antiglomerular basement membrane nephritis.27

Sources of Funding

This study was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-036079 and DK-049870 to C.S.W. and W.J.W. and HL-089583 to W.J.W.) and from the National Heart, Lung and Blood Institute to C.S.W., W.J.W., and A.W. (HL-68686) and by funds from the George E. Schreiner Chair of Nephrology.

Disclosures

None.

Acknowledgments

We thank Wing Kam (Emily) Chan and Glenda Baker for preparing and editing the article.

  • Received January 20, 2011.
  • Revision received February 6, 2011.
  • Accepted July 29, 2011.
  • © 2011 American Heart Association, Inc.

References

  1. 1.↵
    1. Just A
    . Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1–R17.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bidani AK,
    2. Griffin KA,
    3. Williamson G,
    4. Wang X,
    5. Loutzenhiser R
    . Protective importance of the myogenic response in the renal circulation. Hypertens. 2009;54:393–398.
    OpenUrlCrossRef
  3. 3.↵
    1. Just A,
    2. Arendshorst WJ
    . A novel mechanism of renal blood flow autoregulation and the autoregulatory role of A1 adenosine receptors in mice. Am J Physiol Renal Physiol. 2007;293:F1489–F1500.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Wilcox CS
    . Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol. 2005;289:R913–R935.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Wang D,
    2. Chabrashvili T,
    3. Wilcox CS
    . Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane-prostanoid receptors and endothelium. Circ Res. 2004;94:1436–1442.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Carlstrom M,
    2. Lai EY,
    3. Ma Z,
    4. Steege A,
    5. Patzak A,
    6. Eriksson UJ,
    7. Lundberg JO,
    8. Wilcox CS,
    9. Persson AE
    . Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II via modulation of nitric oxide bioavailability. Hypertension. 2010;56:907–913.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Ungvari Z,
    2. Csiszar A,
    3. Huang A,
    4. Kaminski PM,
    5. Wolin MS,
    6. Koller A
    . High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. Circulation. 2003;108:1253–1258.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ren Y,
    2. D'Ambrosio MA,
    3. Liu R,
    4. Pagano PJ,
    5. Garvin JL,
    6. Carretero OA
    . Enhanced myogenic response in the afferent arteriole of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010;298:H1769–H1775.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Sharma K,
    2. Cook A,
    3. Smith M,
    4. Valancius C,
    5. Inscho EW
    . TGF-β impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol. 2005;288:F1069–F1077.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Saeed A,
    2. DiBona GF,
    3. Marcussen N,
    4. Guron G
    . High-NaCl intake impairs dynamic autoregulation of renal blood flow in ANG II-infused rats. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1142–R1149.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Wilcox CS,
    2. Pearlman A
    . Chemistry and antihypertensive effects of tempol and other nitroxides. Pharm Rev. 2008;60:418–469.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Zagorac D,
    2. Yamaura K,
    3. Zhang C,
    4. Roman RJ,
    5. Harder DR
    . The effect of superoxide anion on autoregulation of cerebral blood flow. Stroke. 2005;36:2589–2594.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Just A,
    2. Arendshorst WJ
    . The role of reactive oxygen species in renal blood flow autoregulation [abstract]. FASEB J. 2008;22:761.19.
    OpenUrl
  14. 14.↵
    1. Chen Y,
    2. Pearlman A,
    3. Luo Z,
    4. Wilcox CS
    . Hydrogen peroxide mediates a transient vasorelaxation with tempol during oxidative stress. Am J Physiol. 2007;293:H2085–H2092.
    OpenUrl
  15. 15.↵
    1. Iida Y,
    2. Katusic ZS
    . Mechanisms of cerebral arterial relaxations to hydrogen peroxide. Stroke. 2000;31:2224–2230.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Lai E,
    2. Onozato ML,
    3. Solis G,
    4. Aslam S,
    5. Welch WJ,
    6. Wilcox CS
    . Myogenic responses of mouse isolated perfused renal afferent arterioles: effects of salt intake and reduced renal mass. Hypertens. 2010;55:983–989.
    OpenUrlCrossRef
  17. 17.↵
    1. Beckman JS,
    2. Minor RL Jr.,
    3. White CW,
    4. Repine JE,
    5. Rosen GM,
    6. Freeman BA
    . Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J Biol Chem. 1988;263:6884–6892.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Landmesser U,
    2. Dikalov S,
    3. Price SR,
    4. McCann L,
    5. Fukai T,
    6. Holland SM,
    7. Mitch WE,
    8. Harrison DG
    . Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201–1209.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Wang D,
    2. Luo Z,
    3. Wang X,
    4. Jose PA,
    5. Falck JR,
    6. Welch WJ,
    7. Aslam S,
    8. Teerlink T,
    9. Wilcox CS
    . Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of Tempol. Hypertension. 2010;56:950–955.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Just A,
    2. Arendshorst WJ
    . Nitric oxide blunts myogenic autoregulation in rat renal but not skeletal muscle circulation via tubuloglomerular feedback. J Physiol. 2005;569:959–974.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Juncos LA,
    2. Garvin J,
    3. Carretero OA,
    4. Ito S
    . Flow modulates myogenic responses in isolated microperfused rabbit afferent arterioles via endothelium-derived nitric oxide. J Clin Invest. 1995;95:2741–2748.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Fellner SK,
    2. Arendshorst WJ
    . Angiotensin II, reactive oxygen species, and Ca2+ signaling in afferent arterioles. Am J Physiol Renal Physiol. 2005;289:F1012–F1019.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Wang D,
    2. Jose P,
    3. Wilcox CS
    . β1 Receptors protect the renal afferent arteriole of angiotensin-infused rabbits from norepinephrine-induced oxidative stress. J Am Soc Nephrol. 2006;17:3347–3354.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Harrison D,
    2. Gongora MC,
    3. Guzik TJ,
    4. Widder J
    . Oxidative stress and hypertension. Hypertension. 2007;1:30–44.
    OpenUrl
  25. 25.↵
    1. Schnackenberg CG,
    2. Welch WJ,
    3. Wilcox CS
    . TP receptor-mediated vasoconstriction in microperfused afferent arterioles: role O2- and NO. Am J Physiol. 2000;48:F302–F308.
    OpenUrl
  26. 26.↵
    1. Chen YF,
    2. Cowley AW Jr.,
    3. Zou AP
    . Increased H2O2 counteracts the vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol. 2003;285:R827–R833.
    OpenUrl
  27. 27.↵
    1. Lu H,
    2. Zhen J,
    3. Wu T,
    4. Peng A,
    5. Ye T,
    6. Wang T,
    7. Yu X,
    8. Vaziri ND,
    9. Mohan C,
    10. Zhou XJ
    . Superoxide dismutase mimetic drug tempol aggravates anti-GBM antibody-induced glomerulonephritis in mice. Am J Physiol Renal Physiol. 2010;299:F445–F452.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Asaba K,
    2. Tojo A,
    3. Onozato ML,
    4. Goto A,
    5. Fujita T
    . Double-edged action of SOD mimetic in diabetic nephropathy. J Cardiovasc Pharmacol. 2007;49:13–19.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Chen X,
    2. Patel K,
    3. Connors S,
    4. Mendonca M,
    5. Welch WJ,
    6. Wilcox CS
    . Acute antihypertensive action of tempol in the spontaneously hypertensive rat. Am J Physiol. 2007;293:H3246–H3253.
    OpenUrl
  30. 30.↵
    1. Hahn SM,
    2. Mitchell JB,
    3. Shacter E
    . Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med. 1997;23:879–884.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Krishna MC,
    2. Samuni A,
    3. Taira J,
    4. Goldstein S,
    5. Mitchell JB,
    6. Russo A
    . Stimulation by nitroxides of catalase-like activity of hemeproteins. J Biol Chem. 1996;271:26018–26025.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Schluter T,
    2. Steinbach AC,
    3. Steffen A,
    4. Rettig R,
    5. Grisk O
    . Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition. Cardiovasc Res. 2008;80:271–279.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Lodi F,
    2. Cogolludo A,
    3. Duarte J,
    4. Moreno L,
    5. Coviello A,
    6. Peral De BM,
    7. Vera R,
    8. Galisteo M,
    9. Jimenez R,
    10. Tamargo J,
    11. Perez-Vizcaino F
    . Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. Eur J Pharmacol. 2006;544:97–103.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Hostetter TH,
    2. Olson JL,
    3. Rennke HG,
    4. Venkatachalam MA,
    5. Brenner BM
    . Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85–F93.
    OpenUrlPubMed
  35. 35.↵
    1. Li P,
    2. Mendonca M,
    3. Welch WJ,
    4. Wilcox CS
    . Salt-sensitive hypertension in a model of chronic renal failure is ameliorated by Tempol [abstract]. J Am Soc Nephrol. 2007;18:846A.
    OpenUrlCrossRef
  36. 36.↵
    1. Hobo A,
    2. Yuzawa Y,
    3. Kosugi T,
    4. Kato N,
    5. Asai N,
    6. Sato W,
    7. Maruyama S,
    8. Ito Y,
    9. Kobori H,
    10. Ikematsu S,
    11. Nishiyama A,
    12. Matsuo S,
    13. Kadomatsu K
    . The growth factor midkine regulates the renin-angiotensin system in mice. J Clin Invest. 2009;119:1616–1625.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
October 2011, Volume 58, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods and Protocols
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Superoxide Modulates Myogenic Contractions of Mouse Afferent Arterioles
    En Yin Lai, Anton Wellstein, William J. Welch and Christopher S. Wilcox
    Hypertension. 2011;58:650-656, originally published September 14, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.170472

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Superoxide Modulates Myogenic Contractions of Mouse Afferent Arterioles
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Superoxide Modulates Myogenic Contractions of Mouse Afferent Arterioles
    En Yin Lai, Anton Wellstein, William J. Welch and Christopher S. Wilcox
    Hypertension. 2011;58:650-656, originally published September 14, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.170472
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Endothelium/Vascular Type/Nitric Oxide
    • Vascular Biology
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured